AF710B
AF710B is an orally effective allosteric agonist for the M1 muscarinic receptor and σ1 receptor. AF710B activates the downstream phosphorylated ERK1/2 and phosphorylated CREB signaling pathways. AF710B simultaneously improves cognitive function and alleviates the core pathological features of Alzheimer's disease, including Aβ deposition, excessive Tau phosphorylation and neuroinflammation. AF710B is applicable to the research of Alzheimer's disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C20H27N3OS
- 分子量:357.51
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Sigma Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
AF710B (0.1-10 nM; 3 h) potentiates carbachol-induced ERK1/2 and CREB phosphorylation in starved PC12M1 cells without inducing these responses independently[1].
AF710B (30 nM; 16 h) rescues mushroom spine loss in PS1-KI and APP-KI primary hippocampal neuronal cultures via a mechanism requiring functional M1 mAChRs and intact σ1R expression, with no effect on nTg cultures[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:rat pheochromocytoma PC12 cells stably transfected with rat M1 mAChR (PC12M1 cells)
-
Concentration:0.1, 1 and 10 nM
-
Incubation Time:3 h (pretreatment); 10 min (carbachol treatment)
-
Result:Did not increase phospho-ERK1/2 or phospho-CREB levels independently.
Significantly potentiated carbachol-induced phosphorylation of ERK1/2 and CREB at all tested concentrations.
AF710B (10 µg/kg; i.p.; once daily for 2 months) improves cognitive function in mice, and reduces Aβ pathology, excessive tau phosphorylation, and neuroinflammation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wistar (male and female, 3 months old, 225-250 gr, trihexyphenidyl-induced cognitive impairment)[1]
-
Dosage:1 µg/kg; 3 µg/kg; 10 µg/kg; 30 µg/kg; 100 µg/kg
-
Administration:p.o.; single dose
-
Result:Significantly increased retention latency in trihexyphenidyl-treated rats compared to vehicle-treated trihexyphenidyl rats at 1, 3, 10, and 30 µg/kg doses.
Showed no significant effect at 100 µg/kg dose.
Demonstrated higher potency at 10 µg/kg dose than 100 µg/kg dose.
Lost anti-amnesic effect at 10 µg/kg dose when coadministered with σ1R antagonist NE-100.
-
Animal Model:129/C57BL/6 (female, 10-12 months old, 3xTg-AD Alzheimer's disease model)[1]
-
Dosage:10 µg/kg
-
Administration:i.p.; daily; 2 months
-
Result:Improved cognitive function, as shown by decreased escape latency during Morris water maze training and increased time spent in the target quadrant during the probe trial.
Significantly reduced levels of soluble and insoluble Aβ40 and Aβ42, and decreased Thioflavin S-positive amyloid plaques.
Lowered BACE1 expression and levels of the β-secretase-derived APP C-terminal fragment C99, while leaving full-length APP and α-secretase (ADAM10, ADAM17) levels unchanged.
Reduced total phosphorylated tau (AT-100 epitope) and specific phospho-tau epitopes (AT180, AT270, PHF-1), while total tau levels remained unchanged.
Increased inhibitory Ser9 phosphorylation of GSK3β and reduced levels of the CDK5 activator p25.
Decreased neuroinflammation, as shown by reduced GFAP-positive astrocytes and Iba-1-positive microglia in the vicinity of Aβ plaques.
化学情報
-
分子量 357.51
-
分子式 C20H27N3OS
-
SMILES
C[C@@H]1SC2(CN1C(CCC3=CNC4=C3C=CC=C4)=O)CCN(CC2)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
AF710B 関連分類
HY-116586 関連分類
Powered by Bioz